Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!

Journal of Cachexia, Sarcopenia and Muscle

Volumn 2, Issue 3, 2011, Pages 121-123

  Thum, Thomas ^a,b   Springer, Jochen ^c,d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ANDROSTANOLONE; APPETITE STIMULANT; DRONABINOL; ENOBOSARM; GROWTH FACTOR; GROWTH HORMONE; INSULIN; MEGESTROL ACETATE; NANDROLONE; ORAL ANTIDIABETIC AGENT; OXANDROLONE; OXYMETHOLONE; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ADRENAL SUPPRESSION; ANEMIA; ARTHRALGIA; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BODY MASS; CACHEXIA; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG SAFETY; DRUG TARGETING; EDITORIAL; EUPHORIA; FUNCTIONAL STATUS; HEART VENTRICLE HYPERTROPHY; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGONADISM; INSULIN RESISTANCE; LEAN BODY WEIGHT; MUSCLE STRENGTH; MYALGIA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRILIZATION; WEIGHT GAIN;

EID: 84862891614     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-011-0040-8     Document Type: Editorial

References (21)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12: 489-95.
2. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle. 2010; 1: 1-5.
3. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle. 2011; 2: 9-25.
4. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009; 121: 227-52.
5. Lee NK, MacLean HE. Polyamines, androgens, and skeletal muscle hypertrophy. J Cell Physiol. 2011; 226: 1453-60.
6. Dillon EL, Durham WJ, Urban RJ, Sheffield-Moore M. Hormone treatment and muscle anabolism during aging: androgens. Clin Nutr. 2010; 29: 697-700.
7. Schmidt A, Harada S, Kimmel DB, Bai C, Chen F, Rutledge SJ, et al. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem. 2009; 284: 36367-76.
8. Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, Morton RA, Steiner MS. The selective androgen receptor modulator, GTx-024 (enobosarm), improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011. doi: 10. 1007/s13539-011-0034-6.
9. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010; 1: 7-8.
10. Pascual Lopez A, Roque i Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage. 2004; 27: 360-9.
11. Caparros GC, Zambrana JL, Delgado-Fernandez M, Diez F. Megestrol-induced Cushing syndrome. Ann Pharmacother. 2001; 35: 1208-10.
12. Koller E, Gibert C, Green L, Mann M, Bernstein B. Thrombotic events associated with megestrol acetate in patients with AIDS cachexia. Nutrition. 1999; 15: 294-8.
13. Yeh SS, Lovitt S, Schuster MW. Pharmacological treatment of geriatric cachexia: evidence and safety in perspective. J Am Med Dir Assoc. 2007; 8: 363-77.
14. Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R. Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol. 2010; 11: 679-84.
15. Ho CK, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 2011; 8: 29-41.
16. Unimed pharmaceuticals begins HIV wasting syndrome trial. J Int Assoc Physicians AIDS Care. 1996; 2: 51.
17. Haendler B, Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol Cell Endocrinol. 2011. doi: 10. 1016/j. mce. 2011. 06. 002.
18. Storer TW, Woodhouse LJ, Sattler F, Singh AB, Schroeder ET, Beck K, et al. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment. J Clin Endocrinol Metab. 2005; 90: 4474-82.
19. Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004; 64: 725-50.
20. Mulligan K, Schambelan M. Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. Int J Cardiol. 2002; 85: 151-9.
21. Gelato M, McNurlan M, Freedland E. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther. 2007; 29: 2269-88.